At the time, I never imagined I would get a 'blood disease'.Until then, I had been working normally, living with my family, ...
In a phase 3 randomized clinical trial involving 410 people with early Parkinson disease, 52 weeks of nicotinamide riboside ...
Presentations feature real-world experience and clinical evidence in lower-risk MDS, underscoring growing global scientific engagement with ...
CAN fusion gene and WT1 overexpression reveals how genetic synergy and treatment complications shape outcomes in an ...
The oral combination of azacitidine and cedazuridine (ASTX030) met its primary endpoint in phase 3 AZTOUND study of patients ...
Myelodysplastic syndromes (MDS) belong to the malignant diseases of the hematopoietic system that occur primarily in older ...
TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a ...
A major clinical trial involving 410 people with early Parkinson's disease has found no clinical benefit from nicotinamide ...
Researchers adapted the MDS-NMS tool to assess nonmotor symptoms in Huntington disease (HD), with preliminary results ...
As treatment options for Parkinson disease (PD) continue to expand, clinicians increasingly have to consider when patients ...
Proposed acquisition expected to accelerate development of CERo's lead product candidate, CER-1236, for hematologic malignancies ...
SPV, CERO 1236, to raise capital directly into subsidiary and not dilute existing SRX Global shareholdersProposed acquisition expected to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results